HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 215 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,228,512 | -91.0% | 32,160 | -91.5% | 0.00% | -90.2% |
| Q2 2023 | $13,690,729 | -6.5% | 379,560 | -1.0% | 0.04% | -8.9% |
| Q1 2023 | $14,642,924 | +110.9% | 383,423 | +214.3% | 0.04% | +87.5% |
| Q4 2022 | $6,941,800 | -42.2% | 122,000 | -59.8% | 0.02% | -50.0% |
| Q3 2022 | $12,014,000 | +16.1% | 303,839 | +17.1% | 0.05% | +17.1% |
| Q1 2022 | $10,345,000 | +21.3% | 259,400 | +22.4% | 0.04% | +20.6% |
| Q4 2021 | $8,525,000 | +381.1% | 212,000 | +410.8% | 0.03% | +277.8% |
| Q4 2020 | $1,772,000 | -31.4% | 41,500 | -57.8% | 0.01% | -30.8% |
| Q3 2020 | $2,583,000 | +25.1% | 98,292 | +27.7% | 0.01% | 0.0% |
| Q2 2020 | $2,064,000 | -37.4% | 76,969 | -58.0% | 0.01% | -51.9% |
| Q1 2020 | $3,296,000 | -83.8% | 183,215 | -84.6% | 0.03% | -74.8% |
| Q2 2019 | $20,404,000 | +254.6% | 1,187,660 | +103.9% | 0.11% | +167.5% |
| Q4 2016 | $5,754,000 | – | 582,400 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,816,162 | $195,784,000 | 9.33% |
| BB BIOTECH AG | 5,846,564 | $57,764,000 | 2.74% |
| QVT Financial LP | 4,556,090 | $45,014,000 | 2.44% |
| Parametrica Management Ltd | 29,578 | $292,000 | 2.21% |
| SECTORAL ASSET MANAGEMENT INC | 4,389,682 | $43,370,000 | 1.84% |
| Belmont Global Advisors, Inc. | 257,000 | $2,539,000 | 1.83% |
| HARVEY CAPITAL MANAGEMENT INC | 394,550 | $3,898,000 | 1.40% |
| Lombard Odier Asset Management (USA) Corp | 1,350,000 | $13,338,000 | 0.70% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 6,199,685 | $61,253,000 | 0.63% |
| Callan Capital, LLC | 199,230 | $1,968,000 | 0.53% |